HC's Honest Opinion from the Conf Call/Earnings:
Post# of 405
(Total Views: 2201)
Posted On: 05/12/2017 5:58:26 PM
HC's Honest Opinion from the Conf Call/Earnings:
I am underwhelmed but convinced that share price at year end will be much higher than it is now.
Clearly their main goal is still profitability exiting 2017 but not one word uttered about the $15M guidance. He backed off that which was unfortunate. Now I think we do get over that number but it will take 2-3 months of Fluti sales to do so. The BH platform touches 20M+ people a month and that will be big for Fluti
I heard 60K from SK Zestra deal so far with an upcoming purchase order pending but he still reiterated the 2M minimum from them.
I heard BH platform launching in Canada which should give them another 500k in revenue this year.
I heard increasing products and next one may be in the migraine area
I definitely know that more distribution deals will hit outside of the US which will hit bottom line in a favorable fashion. EU should be next
2.4 Million in current cash
Vesele still #1 selling product and stats from study with Viagara will be released soon. That news should bump PPS and sales of Vesele IMO.
_____________________________________________________________
So, for me, it's a clear hold...I would have absolutely dumped this Monday if FlutiCare was not in the near-term picture. When Flonase can sell $343 Million annually, I am convinced that we can gain at least a 5% market share, which is $17M once this gets up and running. For that, I am happy to buy on dips because that is a future revenue doubler at the very least. On the conservative-side, Fluti gives us 2.5M in revs THIS year.
We went up 500k in revs from Q4 2016 to Q1 2017 but I expected more. Obviously the take rates are lower than .0075. So bottom line, underwhelmed but happy to continue to average down, so bashers, I would love for you to continue to do your thing. Bassam is an excitable guy and was way too eager. He is not a fraud or scammer and is doing some good things. Within 7 months, this stock will be much higher than it is now. I would absolutely voice your displeasure but also provide constructive ideas for them to implement as Fluti will turn this around. The Novalere deal allowed us the right to work with over 20,000 vendors and Fluti will be sold in Q4 because of the rights to these vendors. If not for that and the Hikma deal, this company would be spinning its wheels. HOLD for me, with adding on the dips as PPS will be much higher 7 months from now
I am underwhelmed but convinced that share price at year end will be much higher than it is now.
Clearly their main goal is still profitability exiting 2017 but not one word uttered about the $15M guidance. He backed off that which was unfortunate. Now I think we do get over that number but it will take 2-3 months of Fluti sales to do so. The BH platform touches 20M+ people a month and that will be big for Fluti
I heard 60K from SK Zestra deal so far with an upcoming purchase order pending but he still reiterated the 2M minimum from them.
I heard BH platform launching in Canada which should give them another 500k in revenue this year.
I heard increasing products and next one may be in the migraine area
I definitely know that more distribution deals will hit outside of the US which will hit bottom line in a favorable fashion. EU should be next
2.4 Million in current cash
Vesele still #1 selling product and stats from study with Viagara will be released soon. That news should bump PPS and sales of Vesele IMO.
_____________________________________________________________
So, for me, it's a clear hold...I would have absolutely dumped this Monday if FlutiCare was not in the near-term picture. When Flonase can sell $343 Million annually, I am convinced that we can gain at least a 5% market share, which is $17M once this gets up and running. For that, I am happy to buy on dips because that is a future revenue doubler at the very least. On the conservative-side, Fluti gives us 2.5M in revs THIS year.
We went up 500k in revs from Q4 2016 to Q1 2017 but I expected more. Obviously the take rates are lower than .0075. So bottom line, underwhelmed but happy to continue to average down, so bashers, I would love for you to continue to do your thing. Bassam is an excitable guy and was way too eager. He is not a fraud or scammer and is doing some good things. Within 7 months, this stock will be much higher than it is now. I would absolutely voice your displeasure but also provide constructive ideas for them to implement as Fluti will turn this around. The Novalere deal allowed us the right to work with over 20,000 vendors and Fluti will be sold in Q4 because of the rights to these vendors. If not for that and the Hikma deal, this company would be spinning its wheels. HOLD for me, with adding on the dips as PPS will be much higher 7 months from now
(1)
(0)Innovus Pharmaceuticals Inc. (INNV) Stock Research Links
Scroll down for more posts ▼